{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    24,
    25,
    26,
    27,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "claude-opus-4-5",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "ALXN1840",
        "type": {
          "id": "ac189807-00ea-4bfa-9da0-3ce1f25003b6",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "a11784bc-4d67-4099-b28a-cf3a533fadb8",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Novel copper binding agent (bis-choline tetrathiomolybdate) for treatment of Wilson disease",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "ALXN1840 tablets",
        "administrableDoseForm": {
          "id": "39356a1e-b2a5-4016-be04-51a2d32e8402",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "8398e588-cab2-44f8-b6dc-71d2a453d639",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "1add075f-e26f-4417-a96a-cdd9f1f0ff13",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Alexion Pharmaceuticals"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "ALXN1840 15 mg once daily",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 1 through Day 28 (approximately 28 days)"
      },
      {
        "id": "admin_2",
        "name": "ALXN1840 30 mg once daily",
        "instanceType": "Administration",
        "dose": "30 mg (administered as 2 × 15 mg tablets)",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 29 through Day 39 (11 days)"
      },
      {
        "id": "admin_3",
        "name": "ALXN1840 15 mg every other day (dose reduction)",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "As needed per dose modification criteria"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "bis-choline tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active pharmaceutical ingredient containing tetrathiomolybdic acid (7.8 mg per 15 mg tablet)"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 1,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "ALXN1840",
        "role": "Investigational Product",
        "description": "Novel copper binding agent (bis-choline tetrathiomolybdate) for treatment of Wilson disease"
      }
    ],
    "products": [
      {
        "name": "ALXN1840 tablets",
        "doseForm": "Tablet",
        "strength": "15 mg",
        "manufacturer": "Alexion Pharmaceuticals"
      }
    ],
    "substances": [
      {
        "name": "bis-choline tetrathiomolybdate",
        "description": "Active pharmaceutical ingredient containing tetrathiomolybdic acid (7.8 mg per 15 mg tablet)"
      }
    ],
    "administrations": [
      {
        "name": "ALXN1840 15 mg once daily",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 1 through Day 28 (approximately 28 days)"
      },
      {
        "name": "ALXN1840 30 mg once daily",
        "dose": "30 mg (administered as 2 × 15 mg tablets)",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 29 through Day 39 (11 days)"
      },
      {
        "name": "ALXN1840 15 mg every other day (dose reduction)",
        "dose": "15 mg",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "As needed per dose modification criteria"
      }
    ],
    "devices": []
  }
}